Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term effectiveness of quadrivalent HPV vaccine in Chinese females (V501-041 10- and 15-year follow-up)
ChiCTR2100052313Phase 3Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of qHPV vaccine in Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), cervical adenocarcinoma in situ (AIS) and 4 more (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Cumulative incidence of CIN 2+ related to HPV16/18, Seropositivity rates for HPV6/11/16/18 and 1 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
qHPV vaccine
03
Conditions
Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)cervical adenocarcinoma in situ (AIS)anogenital wartsVulval carcinoma
Beyond the preview
Go deeper on ChiCTR2100052313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052313.